You are here

Human Corneal Model for Ocular Irritation Assay

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43EY018988-01A1
Agency Tracking Number: EY018988
Amount: $233,250.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MATTEK CORPORATION 200 HOMER AVE
ASHLAND, MA 01721
United States
DUNS: 147365936
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (508) 881-6771
Email: mklausner@mattek.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Replacement of the Draize rabbit eye test for ocular irritancy testing remains an elusive goal. Although monolayer cultures and stratified corneal epithelial tissues have been developed and are useful as initial screens
for ocular irritancy, they are not capable of completely modeling the interaction of exogenous chemical with human corneal tissue. For instance, protocols developed with current tissue models correctly identify a high percentage of ocular irritants (~ 95%
) but misclassify a large percentage of non-irritants as irritants (~33%). Also, these models are not capable of modeling extent of injury and time to recovery following chemical insult. Thus, animal or human clinical tests are still needed to gain a compe
te picture of the effects of chemical exposure to the eye. The current application will develop a corneal full thickness (CFT) tissue model compromised of endothelial, stromal, and epithelial components. The CFT tissue will contain human cells and develop
tissue barrier properties that are comparable to native corneal tissue. Because of its improved barrier, the CFT will avoid the misclassification of non-irritants. In addition, the CFT tissue will be useful in determining the extent of injury and time to r
ecovery following noxious chemical exposure. Due to these enhanced capabilities, the CFT will provide toxicologists and scientists with a tool that will dramatically decrease, if not eliminate entirely, the need for animal testing to determine ocular irrit
ancy. PUBLIC HEALTH RELEVANCE: Safety assessment of all new chemicals and products requires evaluation of potential ocular irritancy in case of intentional or unintentional exposure to the eye. Current animal-based test methods are sup-optimal because of a
nimal welfare concerns and in vitro methods lack the complexity required to completely model in vivo responses. We will develop a corneal full thickness tissue and in vitro test methods that will dramatically reduce or eliminate the need to use animals to
assess ocular irritancy of chemicals and products.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government